Rtog 9410

This forum made possible through the generous support of SDN members, donors, and sponsors. Thank you.
Any ideas why the study took so long to publish the data?

-R
 
Members don't see this ad :)
Dr. Zietman gave a great talk on this paper on 8/23 for the ARRO journal club. For prostate cancer it takes a long time to get a difference in OS, particularly when dealing with low or intermediate risk patients.
 
Dr. Zietman gave a great talk on this paper on 8/23 for the ARRO journal club. For prostate cancer it takes a long time to get a difference in OS, particularly when dealing with low or intermediate risk patients.

:)

That's nice and all but RTOG 9410 actually looked at locally advanced lung cancer (Stage IIIA/IIIB) which actually doesn't take very long at all to show differences in clinical endpoints, particularly OS.
 
Sorry for the confusion... I am on the prostate service so seeing prostate everywhere. I was thinking of 94-08. I need to pay attention!
 
Top